Efficacy Results Announced: global first Antibody Mediated Prevention (AMP) trials

Jan 25, 2021
HIV virus neutralized by AMP

HIV virus neutralized by AMP
Graphic credit: HVTN

The proof-of-concept AMP studies demonstrated that a broadly neutralizing antibody (bnAb) called VRC01 was effective at preventing the acquisition of HIV strains that were sensitive to the bnAb. This was assessed by a laboratory test that measures a virus’ susceptibility to neutralization by an antibody.

The two studies (HVTN 704/HPTN 085 and HVTN 703/HPTN 081) opened in April 2016 and successfully enrolled 4,623 participants. The AMP studies are sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The studies are conducted jointly by the HIV Vaccine Trials Network (HVTN) and HIV Prevention Trials Network (HPTN).